


Shiao

ANSWER 5 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN  
ACCESSION NUMBER: 2002:347229 CAPLUS  
DOCUMENT NUMBER: 136:355163  
TITLE: Preparation of acylaminoalkylbenzenesulfonamides as  
cardiovascular agents.  
INVENTOR(S): Heitsch, Holger; Englert, Heinrich Christian  
PATENT ASSIGNEE(S): Aventis Pharma Deutschland G.m.b.H., Germany  
SOURCE: Ger. Offen., 34 pp.  
CODEN: GWXXBX  
DOCUMENT TYPE: Patent  
LANGUAGE: German  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10054481	A1	20020508	DE 2000-10054481	20001103
WO 2002036556	A2	20020510	WO 2001-EP12143	20011020
WO 2002036556	A3	20020704		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002018253	A5	20020515	AU 2002-18253	20011020
EP 1345892	A2	20030924	EP 2001-992696	20011020
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004513109	T2	20040430	JP 2002-539316	20011020
US 2002123494	A1	20020905	US 2001-985366	20011102
US 6511989	B2	20030128		
PRIORITY APPLN. INFO.:			DE 2000-10054481 A	20001103
			WO 2001-EP12143 W	20011020
OTHER SOURCE(S):		MARPAT 136:355163		
GI				



AB Title compds. [I; R1 = halo, alkyl, (substituted) alkoxy, alkenyloxy, PhO, Ph, alkenyl, alkynyl, heteroaryl, PhS, PhSO, PhSO2, etc.; R2 = H, alkyl, cycloalkyl; R3 = H, alkyl; A = quinoline-3-carbonyl, 1-cyclohex-1-enylcarbonyl, 3-methyl-2-butenoyl; X = O, S; Y = [C(R3)2]n; n = 1-4; Z = NH, O; with provisos], were prepared I have an inhibiting effect on ATP sensitive potassium channels in the **heart** muscle and/or the vagal nerve and are suitable for the treatment of reduced **heart** contractility, coronary **heart disease**, arrhythmia, **heart** failure, cardiomyopathy, or vagal dysfunction, or the prevention of sudden **heart** death. Thus, 5-[[2-(3-quinolinecarboxamido)ethyl]-2-[2-(2,2,2-trifluoroethoxy)ethoxy]ethoxy] **benzenesulfonamide** (preparation given) was heated with MeNCS in DMF at

Shiao

80° to give 1-[5-[2-(3-quinolinecarboxamido)ethyl]-2-[2-(2,2,2-trifluoroethoxy)ethoxy]phenylsulfonyl]-3-methylthiourea. The latter at 2  $\mu$ M prolonged hypoxia-shortened APD90 in guinea pig papilloma muscle by 69%.